表紙
市場調査レポート

USV Limited:製品パイプライン分析

USV Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 257866
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
USV Limited:製品パイプライン分析 USV Limited - Product Pipeline Review - 2015
出版日: 2015年03月11日 ページ情報: 英文 29 Pages
概要

当レポートでは、USV Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

USV Limitedの基本情報

USV Limitedの概要

  • 主要情報
  • 企業情報

USV Limited:R&Dの概要

  • 主な治療範囲

USV Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

USV Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

USV Limited:薬剤プロファイル

  • mitiglinide
  • pegfilgrastim
  • becaplermin
  • Epidermal Growth Factor
  • filgrastim
  • glucagon biosimilar

USV Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

USV Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06843CDB

Summary

Global Markets Direct's, 'USV Limited - Product Pipeline Review - 2015', provides an overview of the USV Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of USV Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of USV Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of USV Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the USV Limited's pipeline products

Reasons to buy

  • Evaluate USV Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of USV Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the USV Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of USV Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of USV Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of USV Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • USV Limited Snapshot
    • USV Limited Overview
    • Key Information
    • Key Facts
  • USV Limited - Research and Development Overview
    • Key Therapeutic Areas
  • USV Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • USV Limited - Pipeline Products Glance
    • USV Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • USV Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • USV Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • USV Limited - Drug Profiles
    • mitiglinide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • becaplermin biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epidermal growth factor biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glucagon biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • typhoid fever polysaccharide vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • USV Limited - Pipeline Analysis
    • USV Limited - Pipeline Products by Target
    • USV Limited - Pipeline Products by Route of Administration
    • USV Limited - Pipeline Products by Molecule Type
    • USV Limited - Pipeline Products by Mechanism of Action
  • USV Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • USV Limited, Key Information
  • USV Limited, Key Facts
  • USV Limited - Pipeline by Indication, 2015
  • USV Limited - Pipeline by Stage of Development, 2015
  • USV Limited - Monotherapy Products in Pipeline, 2015
  • USV Limited - Partnered Products in Pipeline, 2015
  • USV Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • USV Limited - Phase III, 2015
  • USV Limited - Phase I, 2015
  • USV Limited - Preclinical, 2015
  • USV Limited - Pipeline by Target, 2015
  • USV Limited - Pipeline by Route of Administration, 2015
  • USV Limited - Pipeline by Molecule Type, 2015
  • USV Limited - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • USV Limited - Pipeline by Top 10 Indication, 2015
  • USV Limited - Pipeline by Stage of Development, 2015
  • USV Limited - Monotherapy Products in Pipeline, 2015
  • USV Limited - Partnered Products in Pipeline, 2015
  • USV Limited - Pipeline by Top 10 Target, 2015
  • USV Limited - Pipeline by Top 10 Route of Administration, 2015
  • USV Limited - Pipeline by Top 10 Molecule Type, 2015
  • USV Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top